Orphan Drug development specialist TMC Pharma has appointed Gordon Cameron to its board as a non-executive director.
Mr Cameron has 25 years' board-level experience in biotech and pharmaceutical services sectors. He started his career with EY, then spent several years in investment
banking at Rothschild before becoming CFO, and then CEO, of international vaccine company Acambis.
For the past 15 years, Mr Cameron has been CFO of Quotient Sciences, an international Contract Development and Manufacturing Organisation and Clinical Research
Organisation.
In 2004, he was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry.
Julie Matthews, chief executive officer of TMC Pharma, said that the new appointment would "enhance our strategic capability and tactical execution as we consolidate
our position as a global leader in the Orphan Drug development market."
Ceuta Group, a global brand building business providing end-to-end outsourcing services in the health and wellness industry has appointed David Wright as a
non-executive board director.
With extensive experience of leading global consumer healthcare companies, David joins Ceuta Group following five years as CEO/President of global pharmaceutical
company, HRA Pharma and six years as Global Head of Boehringer Ingelheim's consumer business.
During his time at HRA Pharma and Boehringer Ingelheim GmBH, David led both companies through substantial organisational and strategy re-design which led to
sustainable growth and profitability.
The company said: "David has a strong belief that combining the right structure, operational priorities and processes, with a strong focus on company culture, are
critical factors in building successful businesses. This approach saw him lead a period of transformation at HRA Pharma resulting in the company's successful
acquisition by Perrigo Company plc."
David will take an active role on the Ceuta Group Board supporting and building the company's strategic vision and priorities. He will also help shape the company's
growth plans on an operational level to ensure Ceuta Group continues to meet client's needs today and into the future.
Northern Ireland will see changes in the regulatory landscape following the issuance of the Windsor Framework on 27th Feb 2023 and the corresponding EU
Commission proposal. An agreement, in principle, has been reached by the UK and EU.
The new path forward of the Windsor Framework marks a turning point in how both the UK and the EU will work together collaboratively and constructively to ensure
that the same medicines are available in Northern Ireland at the same time as they are in the rest of the United Kingdom.
Whilst this is a successful result for Northern Ireland patients, this is major change for companies that have made specific provisions in their supply chains for
Northern Ireland. The supply chains of companies where provisions and changes were made such as introduction of GB specific pack may be impacted as a result.
However, the burden on the UK Pharma supply chain will be eased.
Prime Minister Rishi Sunak walks with European Commission chief Ursula von der Leyen in Windsor on February 27, 2023
Pharma companies will need to carefully consider making changes within their processes and supply chains pending the issuance of clear guidance from the MHRA on
the regulation changes resulting from the Windsor Agreement and the corresponding EU Commission proposed regulatory changes associated with medicinal products
within the Northern Ireland market.
Smooth access to the EU market for Northern Ireland pharmaceutical and medical technology firms has been safeguarded within the constraints of the agreement. The
pragmatic dual-regulatory system protects business, patients and healthcare services, and reflects that it is an essential state function to maintain and oversee
the supply of medicines within the whole United Kingdom.
The UK GDP Association has been established as a non-profit organisation, operating as a Community Interest Company (CIC), with a focus on providing a
broader support network, particularly for small and medium business enterprises and pharmacy wholesalers.
In addition to delivering commercially viable Good Distribution Practice (GDP) consultancy services for simple models with smaller budgets, the association aims
to function as a networking platform for Responsible Persons in the UK.
As members of the association, companies and individuals can gain multiple benefits that will add value to their business through access to knowledge, discounted
training, consultancy services, audit and inspection support, as well as resources like document templates for risk assessments, CAPA, deviations, and more.
Moreover, members can enjoy the benefit of a like-minded support network via a dedicated GDP community hub, providing a platform for discussions, seeking advice,
and fostering new relationships.
"Our mission is to ensure that patient safety, GDP compliance, and excellent quality is paramount in all organisations, regardless of budget," the company said.
Professional leadership bodies from around the world discussed workforce shortages in community pharmacy and other challenges affecting the sector at a global
meeting held in Paris last month.
Delegated from Denmark, Australia, Ireland, New Zealand, Portugal, Spain, US and the UK updated the conference on how the profession was progressing in practice,
technology and workforce development in their respective countries.
The UK was represented at World Pharmacy Council meeting by National Pharmacy Association chair Andrew Lane and chief executive at the Pharmaceutical Services
Negotiating Committee Janet Morrison.
Lane said: "It's very useful to be part of a global network of pharmacy bodies who are all going through similar challenges as we are in the UK. Sharing intelligence
on other pharmacy systems around the world helps us to prepare the right strategy for engaging with the NHS at home.
"Hearing some of the strides in services and digital technology in the profession gives us hope for the future of the sector. It's clear however that key challenges
such as workforce shortages are starting to have an effect in other parts of the world too."
The government, NHS England and the Association of the British Pharmaceutical Industry (ABPI) has begun the negotiations for a new voluntary scheme for
branded medicines pricing on Thursday (4 May).
A new voluntary scheme is expected to take effect from 1 January 2024, replacing the current scheme which came into force in 2019 and ends on 31 December 2023
In their first meeting, the government, NHS England and industry - represented by the ABPI -expected to agree to a shared negotiation aim of working toward a
mutually beneficial agreement that supports better patient outcomes and a healthier population, a financially sustainable NHS, and UK economic growth.
Health Minister, Will Quince, said: "These negotiations will ensure a new scheme continues to deliver value for money by providing significant savings for our
health services, securing access to innovative lifesaving drugs for NHS patients, and helping to reduce waiting times - one of the Prime Minister's 5 priorities.
The current voluntary scheme supports investment in NHS services and saves billions of pounds for the NHS, while also promoting innovations and a successful life
sciences sector.
Increased cooperation between countries is needed to ensure better regulation of online pharmacies, said authors of a new report - 'Online pharmacy operations and distribution of medicines', published by the International Pharmaceutical Federation's (FIP) Community Pharmacy Section.
The report presents findings of a global survey of pharmacy organisations covering various aspects, such as type of medicines supplied by these pharmacies in different countries, how the authenticity of online pharmacies can be verified, and the usage of e-prescriptions and shared patient health records.
Of the 79 countries responding to the survey, 51 per cent acknowledged that no regulation of online pharmacies exists.
A quarter of the respondents reported cases of irresponsible self-medication by consumers who had purchased medicines through online pharmacies.
A lack of regulation creates "an avenue for illegal pharmacies and may impact the overall quality of medicines and services offered to consumers," authors of
the report said.
Lars-Åke Söderlund, immediate past president of FIP's Community Pharmacy Section and co-editor of the report, said that the pandemic has increased preference for online services, including in the pharmacy sector.
The Royal Pharmaceutical Society (RPS) is seeking views of pharmacists to help shape the future of pharmacy practice in England over the next decade.
The RPS's project with The King's Fund, transforming pharmacy practice, aims to develop a vision for the role of pharmacists and pharmacy teams working across
systems, providing patient care and NHS services. It's due to be published at the end of the year.
"From 15 August to 30 September we are asking people to respond to our consultation on six key themes," the RPS said.
"We'll also be holding face-to-face and virtual events in September to hear your views."
The King's Fund has completed a literature review which has helped inform the initial six themes which will be the focus of the consultation, all of which can be
downloaded and read before responding.